Standard Power Development Spółka z Ograniczoną Odpowiedzialnością i Spółka Komandytowa (KRS 0000734775, NIP 6342932247) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. STANDARD POWER DEVELOPMENT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ I operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since June 13, 2018. STANDARD POWER DEVELOPMENT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ I's most recently reported net revenue was 278.2 K PLN for 2022.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Standard Power Development Spółka z Ograniczoną Odpowiedzialnością i
Identity
- Name
- Standard Power Development Spółka z Ograniczoną Odpowiedzialnością i Spółka Komandytowa
- Legal form
- SPÓŁKA KOMANDYTOWA
- Founded
- June 13, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- March 10, 2025
- Founding act
- 30.05.2018
Articles of association history (2)
- May 30, 2018: 30.05.2018
- June 19, 2018: 19.06.2018R.- ZMIANA UMOWY
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Standard Power Development Spółka z Ograniczoną Odpowiedzialnością i
Credibility rating
22.2 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
30
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2019–2022
Current: E (22/100)
Trend: stable (-0.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2019–2022
Current: 4.4 K PLN
Safe: 739.76 PLN
Operational status - Standard Power Development Spółka z Ograniczoną Odpowiedzialnością i
Founded
June 13, 2018
8 years in operation
Legal form
SPÓŁKA KOMANDYTOWA
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
N/A
Shareholders
N/A
Board
N/A
Filed years
4 years
2019–2022 · profitable: 2/4
Registry entries
20
latest: March 10, 2025
Risk signals
Revenue
278.2 K PLN
2022
Net profit
-937.3 K PLN
2022
Assets
12.7 M PLN
2022
Equity
2.0 M PLN
2022
Valuation
5.3 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Standard Power Development Spółka z Ograniczoną Odpowiedzialnością i.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
